Evidence map›Paper›PMID 41114243›Full record

ReviewACS omega2025

It Is Dangerous to Go Alone: Strategies to Optimize PET Biocatalysis and Upcycling through Enzymatic Synergism.

Bruno Rampanelli Dahmer, Jeferson Camargo de Lima, José Fernando Ruggiero Bachega, Troy Wymore, Luis Fernando Saraiva Macedo Timmers

Abstract readReview
In one paragraph

Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bruno Rampanelli DahmerGraduate Program in Biotechnology, Universidade do Vale do Taquari - Univates, Lajeado 95900-000, RS Brazil.
Jeferson Camargo de LimaGraduate Program in Biotechnology, Universidade do Vale do Taquari - Univates, Lajeado 95900-000, RS Brazil.
José Fernando Ruggiero BachegaDepartment of Pharmacosciences, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre 90050-170, RS Brazil.
Troy WymoreDepartment of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6243, United States.
Luis Fernando Saraiva Macedo TimmersGraduate Program in Biotechnology, Universidade do Vale do Taquari - Univates, Lajeado 95900-000, RS Brazil.ORCID https://orcid.org/0000-0003-0399-5376

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current mainstream methods of plastic recycling are inadequate, producing lower-quality polymers, or are cost-inefficient, requiring expensive reagents operating under harsh conditions. Enzymatic biodegradation of poly-(ethylene terephthalate) (PET) plastic was first extensively described in 2005, and several PET degrading enzymes have been identified since then. Recently discovered or developed PET-degrading enzymes are inhibited by the intermediate reaction product, mono-(2-hydroxyethyl) terephthalate (MHET). Therefore, the enzymatic conversion of PET into its original components, terephthalic acid (TPA) and ethylene glycol (EG), is still inefficient. The synergistic cooperation between PET hydrolases and enzymes capable of hydrolyzing released intermediate products can increase reaction efficiency, reduce separation costs, and enable the full recovery of the basic components of PET for their potential conversion into value-added chemicals. This review aims to provide an overview of enzymes capable of degrading intermediate products and potentially solving the heterogeneous product solution problem, their structures and activities, importance, and potential applications in combination with PET hydrolases.

Identifiers

PMID41114243
PMCPMC12529126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.